Recombinant Human Growth Hormone Plus Recombinant Human Insulin-Like Growth Factor-1 Coadministration Therapy in Short Children with Low Insulin-Like Growth Factor-1 and Growth Hormone Sufficiency: Results from a Randomized, Multicenter, Open-Label, Parallel-Group, Active Treatment-Controlled Trial

Philippe F. Backeljauw, Bradley S. Miller, Pascale Dutailly, Aude Houchard, Elizabeth Lawson, Daniel E. Hale, Barry Reiner, Mark A. Sperling, on behalf of the MS316 Study Group

Aims: Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) both contribute to growth. To determine if recombinant human (rh)GH + rhIGF-1 therapy is more effective than rhGH alone to treat short stature, we assessed the efficacy and safety of coadministered rhGH + rhIGF-1 in short children with GH sufficiency and low IGF-1.

Methods: In a 3-year, randomized, multicenter, open-label trial, patients with height SD score ≤ −2.0 and IGF-1 SD score ≤ −1.0 for age and sex, and with stimulated GH ≥ 10 ng/ml for age and sex, were randomized to receive (all doses in μg/kg/day): 45 rhGH alone (group A), 45 rhGH + 50 rhIGF-1 (group B), 45 rhGH + 100 rhIGF-1 (group C) or 45 rhGH + 150 rhIGF-1 (group D). Height velocity (HV) and Δ height SD score were measured. Results: The first-year HV (modified intention-to-treat population) was 9.3 ± 1.7 cm/year (group A), 10.1 ± 1.3 cm/year (group B), 9.7 ± 2.5 cm/year (group C) and 11.2 ± 2.1 cm/year (group D) (p = 0.001 for groups A vs. D). This effect was sustained, resulting in a height SD score improvement during the second and third years. Most treatment-emergent adverse events were mild and transient. Conclusion: In children with short stature, GH sufficiency and low IGF-1, coadministration of rhGH/rhIGF-1 (45/150 μg/kg) significantly accelerated linear growth compared with rhGH alone, with a safety profile similar to the individual monotherapies.

© 2015 S. Karger AG, Basel

Key Words: Short stature · Growth hormone · Insulin-like growth factor-1
Introduction

Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) have growth-promoting effects through both overlapping and complementary actions [1]. For normal growth to occur, optimal exposure to the actions of both GH and IGF-1 are required. In several animal models, including hypophysectomized rats and knockout mice, defects of the GH–IGF-1 axis cause severe growth failure [2, 3]. In human IGF-1 insufficiency, due to either GH deficiency or GH insensitivity, childhood growth failure results, and, if left untreated, leads to variable degrees of short stature in adulthood [4, 5]. Treatment with recombinant human (rh)GH for GH deficiency [6] or with rhIGF-1 for IGF-1 deficiency (IGFD) [5] improves linear growth, but does not always result in normalization of adult height. Treatment outcome is influenced by multiple factors (including genetics and nutrition), but may also be limited by the inability to adequately correct the abnormalities of the GH–IGF axis with either rhGH or rhIGF-1 monotherapy [7]. For example, in children with short stature and low IGF-1, weight-based rhGH dosing does not consistently result in serum IGF-1 normalization, and IGF-1-based dosing to reach serum IGF-1 titration targets may require three times the recommended rhGH dose [8, 9]. In addition, with rhIGF-1 monotherapy, suppression of nocturnal GH secretion may negatively affect the growth response [10].

GH has specific properties that differ from those of IGF-1, such as (pre)chondrocyte differentiation and lipolysis. The effect of both hormones has been demonstrated to be additive with coadministration in rodents [11, 12]. In addition, combined administration of rhGH and rhIGF-1 is more anabolic in calorie-restricted adults [13]. Combining rhGH with rhIGF-1 therapy to take advantage of their synergistic actions may provide greater efficacy than either rhGH or rhIGF-1 alone.

This study is the first to evaluate the potential benefit of rhGH/rhIGF-1 combination therapy in GH-sufficient children with short stature and low IGF-1, compared with a control group of children treated with rhGH monotherapy.

Materials and Methods

Patients

Patients with short stature (defined as height SD score ≤−2.0 for age and sex), low IGF-1 (IGF-1 SD score ≤−1.0 for age and sex) and GH sufficiency (maximum stimulated GH ≥10 ng/ml) were recruited from 27 US pediatric endocrinology centers. Eligible patients were treatment-naïve, prepubertal, ≥5 years in age, with bone ages (BAs) ≤9 years (girls) or ≤11 years (boys), BMI ≥5th percentile for age and sex, and normal screening laboratory findings. Exclusion criteria comprised the presence of identifiable syndromes, severe IGFD (height and IGF-1 SD score ≤−3 and stimulated GH response ≥10 ng/ml), chronic illnesses that could affect treatment outcomes (e.g. active neoplasm, or congenital and acquired pituitary disease), previous or current use of growth-altering medication (e.g. rhGH, rhIGF-1, sex steroids, gonadotropin agonists), use of attention-deficit/hyperactivity disorder medication or glucocorticoids within 3 months of study entry, and allergy to study drugs.

The protocol was approved by each local institutional review board and/or by the Independent Review Consulting Inc. institutional review board (www.clinicaltrials.gov; identifier: NCT00572156). Parents or legally authorized representatives provided informed consent prior to any study-related activities.

Study Design

This was a randomized, multicenter, open-label, active treatment-controlled, parallel-group, dose-comparison, phase 2 clinical trial (3 years’ duration). After successful screening, patients were randomized to 1 of 4 groups (all doses in μg/kg/day): 45 rhGH alone (group A), 45 rhGH + 50 rhIGF-1 (group B), 45 rhGH + 100 rhIGF-1 (group C) or 45 rhGH + 150 rhIGF-1 (group D). The study arms were stratified by age (≤9 years) and IGF-1 SD score ≤−2 in a 1:1:1:1 ratio (fig. 1). Patients received once daily (morning) s.c. injections of either 45 μg rhGH/kg/day alone [Nutropin AQ®, somatropin (rDNA) injection; Genentech Inc., South San Francisco, Calif., USA] or 45 μg rhGH/kg/day as one injection plus 50, 100 or 150 μg rhIGF-1/kg/day [Increlex®, mecasermin (rDNA) injection; Ipsen Biopharmaceuticals Inc., Basking Ridge, N.J., USA] as a separate s.c. injection in contralateral sites. Treatment was initiated at 50% of the assigned rhGH/rhIGF-1 dose, and increased to the full dose on treatment day 15. A dose-reduction guideline was implemented to ensure patient safety in light of the unknown effect of prolonged exposure to high IGF-1 concentrations. At the discretion of the investigator and after consultation with the study sponsor, patients experiencing a near-peak serum IGF-1 SD score >+4 on ≥2 occasions were instructed to take a reduced dose at the same rhGH-to-rhIGF-1 ratio. Up to two dose reductions were allowed.

The primary endpoint was first-year height velocity (HV). Secondary endpoints included HV during the second and third years; change in height SD score (years 1–3); change in BA; change in BMI; change in GH, IGF-1 and IGF-binding protein 3 (IGFBP-3), and safety monitoring. Height SD score was calculated using the National Center for Health Statistics 2000 data as provided by the Centers for Disease Control and Prevention [14].

After screening, patients were evaluated at baseline and weeks 2, 4, 13, 26, 39, 52, 68, 86, 104, 120, 138 and 156. At each visit, patients had a physical examination (including vital signs, height, weight and fundi), and adverse events were reviewed. Treatment compliance was monitored using patients’ drug administration diaries, study drug dispensing records and measurement of serum GH, IGF-1 and IGFBP-3 at each visit.

Bone Age

To determine the BA, left hand and wrist radiographs were obtained at screening and thereafter annually (years 1–3), and evaluated centrally (LifeSpan Research Inc., Kettering, Ohio, USA). Radiographs performed up to 6 months prior to screening could also be used in place of the screening radiograph.
also used to compare HV between groups during the second and third year for the mITT population. Height SD score was imputed for years 1–3 only if a patient had at least one height value recorded in the specified year. HVs were imputed assuming no change in height SD score after the last measurement. All imputation (i.e. substitution for missing values) was done using the last observation carried forward method.

The ANCOVAs were also done on the completer populations (patients who completed each year of the study). Changes in height SD score within the mITT and completer populations were analyzed with ANCOVA using randomization strata defined by baseline age and IGF-1 SD score as covariates. A similar analysis was also done using subgroups of pubertal patients within the completer populations. All p values were two-sided.

Post hoc ANCOVA on Roche-Wainer-Thissen (RWT) predicted adult height (PAH) was performed adjusting for baseline age and IGF-1 SD score and using the multiple Dunnett adjustment. Student’s t test was performed to analyze the difference in BMI between baseline and the end of the study.

Results

The study was conducted between January 2008 and March 2012, and 106 patients were randomized to treatment. One patient initially randomized to receive rhGH monotherapy was subsequently found to be GH deficient and was removed from the study. The enrollment characteristics were similar for the four subgroups (table 1). The majority of patients were male (80.2%). Overall mean ± SD age was 8.8 ± 2.1 years, height SD score was −2.5 ± 0.4, IGF-1 SD score was −1.9 ± 0.6, BA was 7.3 ± 1.9 years and BMI SD score was −0.4 ± 0.7. A total of 22 patients (n = 6, 3, 5 and 8 in groups A, B, C and D, respectively) were deemed to have entered puberty (breast/teestes Tanner stage 2) during the first year of the study, at ages ranging from 9.3 to 14.4 years in males and 8.7 to 14.4 years in females.
12.9 years in females. Only one patient reached Tanner stage 3 in the first year of the study, a male in group A at age 12.8 years.

Assessment of compliance for both rhGH and rhIGF-1 injections in all groups using patient diaries demonstrated that 75% of patients missed fewer than 13% of their doses. The total cumulative average rhIGF-1 dose (mean ± SD in μg/kg) for completers was 48.7 ± 2.2 (group B, target dose: 50 μg/kg), 87.8 ± 14.8 (group C, target dose: 100 μg/kg) and 132.8 ± 20.2 (group D, target dose: 150 μg/kg). The total cumulative average rhGH dose (mean ± SD in μg/kg) was 44.1 ± 2.5, 44.1 ± 1.2, 39.5 ± 6.7 and 40.0 ± 6.0 for groups A–D, respectively (target dose: 45 μg/kg). The mITT population consisted of 105 patients in year 1, 94 in year 2 and 85 in year 3.

**Table 1. Enrollment characteristics by dosing group**

<table>
<thead>
<tr>
<th></th>
<th>Group A (n = 26)</th>
<th>Group B (n = 27)</th>
<th>Group C (n = 27)</th>
<th>Group D (n = 26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, %</td>
<td>19</td>
<td>19</td>
<td>26</td>
<td>15</td>
</tr>
<tr>
<td>Chronological age, years</td>
<td>9.2±2.0</td>
<td>8.4±2.0</td>
<td>9.0±2.2</td>
<td>8.8±2.3</td>
</tr>
<tr>
<td>Imputed BA, years</td>
<td>7.6±1.7</td>
<td>7.2±1.8</td>
<td>7.2±2.0</td>
<td>7.3±2.0</td>
</tr>
<tr>
<td>Height, cm</td>
<td>119.1±10.0</td>
<td>115.8±9.5</td>
<td>117.7±11.5</td>
<td>116.7±11.8</td>
</tr>
<tr>
<td>Height SD score</td>
<td>−2.5±0.5</td>
<td>−2.5±0.4</td>
<td>−2.6±0.4</td>
<td>−2.6±0.4</td>
</tr>
<tr>
<td>Mother’s height, cm</td>
<td>157±5</td>
<td>157±5</td>
<td>157±6</td>
<td>159±7</td>
</tr>
<tr>
<td>Father’s height, cm</td>
<td>172±4</td>
<td>169±5</td>
<td>173±7</td>
<td>172±6</td>
</tr>
<tr>
<td>Weight SD score</td>
<td>−2.0±0.7</td>
<td>−2.1±0.6</td>
<td>−2.0±0.7</td>
<td>−2.2±0.9</td>
</tr>
<tr>
<td>BMI SD score</td>
<td>−0.3±0.7</td>
<td>−0.5±0.7</td>
<td>−0.4±0.7</td>
<td>−0.5±0.8</td>
</tr>
<tr>
<td>IGF-1 SD score</td>
<td>−1.8±0.5</td>
<td>−2.0±0.7</td>
<td>−1.8±0.6</td>
<td>−2.0±0.6</td>
</tr>
<tr>
<td>IGFBP-3 SD score</td>
<td>−1.1±0.7</td>
<td>−1.2±0.9</td>
<td>−1.0±0.8</td>
<td>−1.3±0.8</td>
</tr>
<tr>
<td>Maximum stimulated GH, ng/ml</td>
<td>17.9±8.9</td>
<td>18.2±8.4</td>
<td>19.5±6.3</td>
<td>20.1±8.4</td>
</tr>
</tbody>
</table>

Values are means ± SD. Unless specified: group A = 45 μg/kg rhGH alone; group B = 45 μg/kg rhGH + 50 μg/kg rhIGF-1; group C = 45 μg/kg rhGH + 100 μg/kg rhIGF-1; group D = 45 μg/kg rhGH + 150 μg/kg rhIGF-1.

**Primary Efficacy Endpoint: First-Year HV**

The first-year HV within the mITT population was 9.3 ± 1.7 cm/year in group A (n = 25), 10.1 ± 1.3 cm/year in group B (n = 27), 9.7 ± 2.5 cm/year in group C (n = 27) and 11.2 ± 2.1 cm/year in group D (n = 26; fig. 2; online suppl. fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000371799). The difference between groups A and D was statistically significant (p = 0.001). ANCOVA of patients completing 1 year of therapy yielded the same result. The statistical significance observed in the primary analysis was not affected by pubertal status, BA or presence/absence of anti-IGF-1 antibodies.

**Fig. 2.** Evolution of height velocity (mean ± SD, mITT population). Group A = 45 μg/kg rhGH alone; group B = 45 μg/kg rhGH + 50 μg/kg rhIGF-1; group C = 45 μg/kg rhGH + 100 μg/kg rhIGF-1; group D = 45 μg/kg rhGH + 150 μg/kg rhIGF-1. *p = 0.001 vs. rhGH alone, Dunnett’s adjustment.
Secondary Efficacy Endpoints: HV during the Second and Third Years of Treatment, and Cumulative Change in Height SD Score during the First, Second and Third Years of Treatment

During the second year of therapy, HV was greater in the coadministration groups than in group A, although these differences were not statistically significant (fig. 2). Third-year HV ranged from 6.8 (group B) to 7.6 (group C) with higher HV observed in group A compared with groups B and D.

The cumulative Δ height SD score over 3 years for the mITT population is shown in figure 3. The first-year Δ height SD scores (mean ± SD, cm/year) were: group A, 0.7 ± 0.3 (n = 22); group B, 0.9 ± 0.2 (n = 22); group C, 0.9 ± 0.4 (n = 20), and group D, 1.0 ± 0.3 (n = 22). The difference in Δ height SD score was statistically significant for the highest two dose combination groups (group C vs. group A: p = 0.05; group D vs. group A: p < 0.0001). The effect seen in group D on cumulative change in height SD score compared with group A was sustained during the second and third years of therapy. After 3 years the cumulative height SD score gains were 1.3, 1.6, 1.8 and 1.9 in groups A–D, respectively, with significant differences observed between groups C and D versus group A (p = 0.008 and 0.002).

Skeletal Maturation

Baseline BA was delayed in relation to chronological age and increased in all treatment groups. The change in BA (years, ±SD) from baseline to year 1 was of a similar magnitude in all treatment groups: group A, 1.2 ± 0.5 (n = 24); group B, 1.3 ± 0.5 (n = 25); group C, 1.2 ± 0.4 (n = 22), and group D, 1.3 ± 1.1 (n = 22). The advancement in BA by year 3 was comparable in the coadministration groups versus the rhGH alone group: group B, 4.0 ± 0.6 (n = 20); group C, 4.0 ± 1.1 (n = 20), and group D, 4.0 ± 0.9 (n = 20), versus group A, 3.8 ± 1.0 (n = 21). These data indicate that increased growth (in the combination groups vs. the GH alone group) was not accompanied by undue skeletal maturation.

Predicted Adult Height

The RWT method for PAH [15], refined by Khamis and Guo [16], and adjusted for growth after age 18 years according to Roche and Davila [17], was calculated at baseline and for each year of therapy for all patients. All four treatment groups demonstrated an improvement in RWT-PAH SD score at year 1, with higher changes (mean ± SD) observed in the three coadministration groups: group A, 0.53 ± 0.36 (n = 24); group B, 0.63 ± 0.21 (n = 25); group C, 0.67 ± 0.37 (n = 22), and group D,
0.76 ± 0.31 (n = 25). In a post hoc analysis, a statistically significant difference (p < 0.05) was met when comparing group A versus group D. The RWT-PAH improvement was sustained during the second and third years of treatment and remained higher in the three coadministration groups. The greatest increase in RWT-PAH SD score was observed during the first year, in line with the catch-up HV observed in that year. Details are provided in online supplementary table 1.

Total Change in BMI

Baseline BMI SD score was not as low as the height SD score (−0.4 ± 0.7 vs. −2.5 ± 0.4). A Student’s t test was performed to analyze whether there was a change in BMI between baseline and the end of study. The results demonstrated an increase in BMI SD score at the end of study compared with baseline (p < 0.005 in all four groups). This was most noticeable in the coadministration groups: mean change in BMI SD score from baseline was 0.45, 0.42 and 0.64, respectively, in groups B–D (vs. 0.34 in group A).

Changes in Serum Concentrations of GH, IGF-1, IGFBP, Acid-Labile Subunit, and GH-Binding Protein

Trough serum GH and GH-binding protein values were highly variable in all treatment arms. Mean trough IGF-1 increased with therapy, and a bigger increase was observed in the coadministration groups. There was no evidence of a clear dose effect or of a correlation between trough IGF-1 and HV. The IGF-1 SD score for the mITT population is shown in figure 4a. For near-peak IGF-1 SD score values (i.e. those taken 2–4 h after study injections), there was an increase between weeks 39 and 120 for all groups. However, IGF-1 decreased after week 120 in the coadministration groups, possibly due to discretionary dose reductions done if IGF-1 SD score >+4. The mean near-peak IGF-1 SD score was at least +2.5 SD between weeks 39 and 120 in both groups C and D. The mean trough IGF-1 in group A at 1 month was 207.9 ng/ml, which was similar to the mean trough IGF-1 in the coadministration groups (206.5, 205.3 and 213.3 ng/ml for groups B–D, respectively), with SDs ranging from 84.4 to 119.0 within each of the four groups. Mean trough IGF-1 values during subsequent years tended to be higher in the coadministration groups (groups B–D) than in group A (year 1: 327, 398 and 296 vs. 278 ng/ml; year 2: 427, 539 and 466 vs. 312 ng/ml; year 3: 405, 462 and 441 vs. 335 ng/ml, respectively). Mean trough IGF-1 SD scores during these subsequent years were therefore: year 1 = 1.12 ± 1.06, 1.42 ± 1.08 and 0.70 ± 1.12 (groups B–D) versus 0.37 ± 0.78 (group A); year 2 = 1.67 ± 1.42, 2.26 ± 0.99 and 1.85 ± 1.19 (groups B–D) versus 0.50 ± 0.64 (group A), and year 3 = 1.30 ± 1.26, 1.54 ± 1.07 and 1.41 ± 1.44 (groups B–D) versus 0.52 ± 0.81 (group A). The mean trough IGFBP-1 SD score remained within the normal range in years 1–3 in all groups, but was slightly higher than +2 SD (+2.26) in group C and close to +2 SD (+1.85) in group D. The number of patients with a trough IGFBP-1 SD score ≥+2 is shown in online supplementary table 2.

The IGFBP-3 SD score for the mITT population is shown in figure 4b. At 1 month of therapy, trough IGFBP-3 was 2,852, 2,469, 2,346 and 2,427 ng/ml for groups A–D, respectively, with SDs varying between 384 and 908 ng/ml across the groups. During subsequent years, IGFBP-3 increased in all groups with the same magnitude and remained normal. Mean trough IGFBP-3 ranged from 2,624 ng/ml or −0.38 SD score (group D) to 2,954 ng/ml or −0.07 SD score (group A) at year 1, 2,755 ng/ml or −0.35 SD score (group D) to 3,060 ng/ml or 0.05 SD score (group C) at year 2, and 3,260 ng/ml or 0.26 SD score (group D) to 3,432 ng/ml or 0.56 SD score (group B) at year 3. The acid-labile subunit (ALS) showed a similar upward trend in all treatment groups: mean trough ALS ranged from 11.5 mg/l (group D) to 16.0 mg/l (group A) at year 1, 13.7 mg/l (group D) to 15.7 mg/l (group C) at year 2 and 11.2 mg/l (group D) to 13.7 mg/l (group A) at year 3. IGFBP-1 declined with the same average magnitude in all groups and all values remained in the normal range throughout (data not shown).

Safety

Each patient reported at least one treatment-emergent adverse event (TEAE) over the course of the study (table 2). The number of TEAEs was 374, 406, 392 and 513 in groups A–D, respectively, with these treatment differences mostly being driven by the variation of mild to moderate adverse events. The number of severe adverse events was similar in each of the groups. Most events were transient and not considered drug related: >80% of TEAEs within each group were of mild severity. Ten patients withdrew from the study because of a TEAE (table 2). In 6 of these cases (patients with injection site pain (2 patients), alopecia, neck pain, urticaria and drug hypersensitivity), the events were considered related to treatment. Five of these related events were of moderate intensity and one was of mild intensity. One of the events considered to be unrelated to study treatment (Evan’s syndrome) was classified by the investigator as a serious adverse event. Previous studies have identified several ad-
verse events of special interest that may be associated with rhIGF-1 exposure and these were monitored in the study.

Headache was reported with the highest incidence: in 14/26 patients (54%) with 40 occurrences in group A, in 14/27 patients (52%) with 43 occurrences in group B, in 17/27 patients (63%) with 39 occurrences in group C and in 18/26 (69%) with 50 occurrences in group D. Headaches were reported earlier by patients treated with coadministration therapy (median 19 days; n = 80) than with rhGH monotherapy (median 73 days; n = 26). The percentage of patients experiencing a first headache increased with increasing rhIGF-1 dose in the earlier stage of the study (i.e. at month 8: 38, 44, 48 and 62% of the patients in groups A–D, respectively, had experienced their first headache). This trend was less apparent in later phases of the study (after month 16). Most headaches were not severe, were transient in nature, and were not a cause of refusal to treat.

Of the adverse events of special interest, injection site lipohypertrophy (a known insulin-like effect of rhIGF-1 therapy [5, 7]) was reported in 16 patients, all receiving coadministration therapy: 6/27, 7/27 and 3/26 in groups B–D, respectively. Tonsil or adenoid hypertrophy was reported at a greater frequency in group A (4/26; 15%) compared with the combination groups (4/80; 5%). Vomiting occurred in 9/26 (35%) of patients in the rhGH alone
group, and in 23/80 (29%) of those receiving coadministration therapy, but the incidence of vomiting was higher in group D than in all other groups (12/26; 46%). Vomiting was not always associated with headaches (in most patients it was not) or hypoglycemia. It occurred with a variety of other reported adverse events (e.g. influenza, gastroenteritis). There were 11 occurrences of hypoglycemia in 9 patients (reported with or without blood measurements). Two (out of 26) patients were from group A, and 7/27 were from group D; all but one were mild episodes. In 3 patients, hypoglycemia resolved spontaneously, while in 3 other patients it resolved following unspecified treatment (most likely food and/or juice). No information on treatment was reported for the remaining 3 patients. None required dose reduction. Two patients (8%) experienced urticaria in the rhGH alone group, compared with 7 patients (9%) in the combination groups (table 2; online suppl. fig. 2).

Five patients experienced serious adverse events during the study. In 2 of the patients, the event was considered ‘related to treatment’ by the investigator. The first patient, an 11-year-old male, had been randomized to group D. He developed papilledema of moderate intensity approximately 6 weeks after treatment start. Magnetic resonance imaging (MRI) of the head was normal. Treatment was suspended for 70 days, before being restarted at a reduced dose of 33.75 μg/kg/day rhGH + 125.5 μg/kg/day rhIGF-1; a further increase to the initial dose 12 weeks later did not result in recurrence of papilledema. This patient subsequently had IGF-1 SD scores >+2 on day 234 (approx. 7 weeks after the dose increase), as well as on days 597 and 729. The first two of these measure-
ments were unscheduled and it is not known whether they were peak or trough measurements, and the last value was a trough measurement. The doses of study drugs were reduced on day 613 as a result of elevated peak IGF-1 values. This patient's presentation was indicative of intracranial hypertension (ICH), but a confirmatory lumbar puncture was refused by the family. The second patient was a 7.5-year-old female who had been randomized to group C. After approximately 6 weeks she developed ICH and was hospitalized for head MRI and confirmatory lumbar puncture. Treatment was suspended and the ICH resolved after 14 days. Treatment was then re-started at a lower dose (33 μg/kg/day rhGH + 75 μg/kg/day rhIGF-1) on day 133 without recurrence of the ICH. IGF-1 SD score was elevated (>+2) in this patient on the day of the onset of ICH and approximately 11 weeks later (day 133). However, both of these assessments were unscheduled and it is not known whether they were peak or trough measurements. In the 3 remaining patients the serious adverse events were considered to be unrelated to treatment by the investigator and comprised a fractured arm and viral gastroenteritis in 1 patient each, and, in a single patient, Evan’s syndrome, with thrombocytopenia, viral infection and hematuria.

Additional Laboratory Evaluation

No new safety signals were identified upon review of the laboratory data. Mean glycosylated hemoglobin increased slightly but remained normal in all groups. At year 3, mean percent glycosylated hemoglobin increase from day 1 was 0.6 for group A (n = 20), 0.5 for group B (n = 19), 0.5 for group C (n = 17) and 0.7 for group D (n = 19). Over the 3 years of the trial, elevations in glycosylated hemoglobin (above the normal range) were reported in 18 patients (group A: 8, group B: 1, group C: 4 and group D: 5). Mean blood glucose was normal throughout the study. No long-term effect of treatment on total, high-density lipoprotein cholesterol or triglycerides outside the normal range. At year 3, 44 out of 80 patients (55%) assigned to 1 of the 3 coadministration groups had developed anti-IGF-1 antibodies, which were transient in most cases.

Discussion

This is the first study to test the effects of coadministration of rhGH and rhIGF-1 in children who have GH sufficiency with low IGF-1 and short stature. Whether such patients would benefit from combined rhGH + rhIGF-I therapy to correct both the short stature and the biochemical abnormalities has been a debated scientific topic in the field of pediatric endocrinology for many years. Some have argued that rhGH alone would be sufficient to treat short stature considering that rhGH is an agent with a known safety profile. Therefore, our study was undertaken to test the hypothesis that in such children, coadministered therapy would result in better growth without undue side effects. The results of our study showed a statistically significant improvement in linear growth for the 45 rhGH + 150 rhIGF-1 group (group D) compared with the rhGH alone group at 1 year. The significant difference in HV observed at year 1 clearly affected the treatment response assessed at years 2 and 3. The HVs for the entire first 2 years (year 1 + year 2) and for all 3 years (year 1 + year 2 + year 3) remained significantly different. However, the true year 2 and year 3 HV did not achieve significant difference (p = 0.063 and p = 0.872). Therefore, rhGH/rhIGF-1 coadministration resulted in significantly greater HV at year 1 only, while still producing an overall greater height gain over the 3 years of the study. This occurred without an undue increase in skeletal maturation or BMI.

The mean first-year HV of 11.2 cm/year for the 45 rhGH + 150 rhIGF-1-treated patients in this study was superior to that of rhIGF-1-treated patients with severe primary IGFD (8.0 cm/year at doses of 40–120 μg/kg/dose twice daily) [5], of IGF-1-treated children with milder IGFD (height and IGF-1 SD scores <-2; 7.0 and 7.9 cm/year at doses of 80 and 120 μg/kg once daily) [18], of rhGH-treated children with idiopathic short stature (7.3–8.6 cm/year at rhGH doses of 33–53 μg/kg/day) [9, 19–21] and was close to the mean HV of 10 cm/year to 13 cm/year previously reported in rhGH-treated children with GH deficiency [6, 22]. The first-year HV for the 45 rhGH alone group in our study was also robust, possibly related to study design, including use of a generous rhGH dose and the inclusion of a few children deemed to have entered puberty, but overall still a slightly younger patient population with younger BA compared with other idiopathic short stature populations in rhGH trials [21, 23]. However, caution should be used when comparing trials with differing inclusion criteria and study design [24]. Nevertheless, compared with most studies of rhGH therapy for
idiopathic short stature, coadministration therapy with lower rhIGF-1 doses (45 rhGH/50 rhIGF-1 or 45 rhGH/100 rhIGF-1) yielded better HV responses than with rhGH alone. Given that we observed a trend toward increasing significance with these increasing rhIGF-1 doses, it is conceivable that certain patients may grow quite well with a lower-dosed coadministration regimen, and, therefore, further investigation should be considered.

The favorable response observed with 45 rhGH + 150 rhIGF-1 coadministration therapy may be due to the additional growth-promoting effect from rhIGF-1 superimposed on that of rhGH therapy within a normal IGFBP-3 and ALS setting. Unlike patients with severe GH insensitivity, the patients in this study had normal IGFBP-3 and ALS, which may lead to increased tissue concentrations of IGF-1, including at the growth plate. One could propose that exogenous GH administration could stimulate the growth plate’s resting zone (pre)chondrocyte differentiation and facilitate chondrocyte maturation at all differentiation stages. The added rhIGF-1 treatment may then further mediate chondrocyte maturation, thus allowing for accelerated longitudinal bone growth. The additive effects of combined rhGH and rhIGF-1 therapy on growth have also been documented in hypophysectomized, dwarf and obese Zucker diabetic rats [11, 12]. Moreover, there may be a greater anabolic effect with this combination than with either hormone alone. In adult humans, rhGH + rhIGF-1 are substantially more anabolic than either one alone [13, 25, 26]. However, it should be noted that we were not able to show a correlation between the HV response and trough IGF-1 concentrations. There appeared to be no influence on the pharmacokinetics of GH (data not shown). The concentrations of IGFBP-3 increased in all treatment groups, indicating that potential suppression of endogenous GH secretion by administration of rhIGF-1 was likely compensated by a stimulatory effect from the exogenously administered rhGH.

As the effects of prolonged exposure to increased IGF-1 concentrations are not known – with the exception of the information gained from studying patients with acromegaly – the investigators were asked to implement dose reductions of drug in patients with IGF-1 SD scores of >+4 on ≥2 occasions. Trough IGF-1 concentrations increased in all groups, and most of all in the combination groups, as did peak IGF-1 concentrations until week 120. However, we found no correlation between trough IGF-1 values and the time to occurrence of first headache, and we also did not observe changes in facial features. Because we could not show a trend indicating that increased IGF-1 concentrations are associated with better HVs, these dose reductions appear to be warranted. As a result of these dose reductions and missed injections, patients tended not to reach their target rhIGF-1 doses (i.e. 50 μg/kg in group B, 100 μg/kg in group C and 150 μg/kg in group D). More frequent dose reductions together with greater change in BA from baseline to year 3 in group D compared with the other groups may account for the lower HV observed in group D at year 3.

The safety profiles of rhGH and rhIGF-1 overlap in some areas, such as for symptoms associated with ICH, while some are distinct to rhIGF-1, such as the potential for hypoglycemia. No additional safety concerns with co-administration were noted compared with previously reported individual safety profiles [7, 20, 27]. The combined safety profile was not markedly different from that of rhGH or rhIGF-1 alone.

ICH was reported in 2 patients receiving coadministered therapy, at a similar incidence to that previously reported [18]. ICH is a documented side effect of both rhGH and rhIGF-1 therapies, although it appears to be a less common occurrence with rhGH therapy than with rhIGF-1 [5, 28]. Because ICH can occur with either hormone used as monotherapy, there may be more concern about the development of ICH than with rhGH or rhIGF-1 monotherapy alone, and its prevalence will need to be monitored in further studies. Most cases of ICH are benign and, with appropriate management, reversible, without the need to permanently discontinue therapy. Education of treating physicians is critical to ensure that they monitor for ICH, to allow for appropriate, early treatment and to prevent unnecessary complications. Fundus examinations are, therefore, recommended at initiation of rhIGF-1 therapy, routinely during the course of therapy and upon occurrence of clinical symptoms (e.g. visual disturbances, headache, nausea and/or vomiting).

More adverse events of special interest, including headache and hypoglycemia, were reported in group D. IGF-1, on a molar basis, only has a fraction of insulin’s effect on glucose metabolism, but after administration of exogenous IGF-1 it may be present in a high enough concentration to reduce glucose availability [29]. Exogenous GH may decrease insulin sensitivity [30], and could counteract the hypoglycemic effect sometimes observed with rhIGF-1 treatment. The assumption that the addition of rhIGF-1 to rhGH would counterbalance the effect of rhGH alone on carbohydrate metabolism was confirmed in this study, but the hypoglycemic events that occurred in group D were of mild intensity and did not necessitate a dose reduction. Furthermore, a greater propor-

rhGH/rhIGF-1 Therapy for Short Stature

DOI: 10.1159/000371799
tion of patients in group A had elevated glycosylated hemoglobin than in the coadministration groups. Hypoglycemia is a known adverse event with rhIGF-1 therapy and specific guidance is provided to physicians prescribing rhIGF-1 therapy for severe primary IGFD to minimize the risk of hypoglycemia. This includes administering all rhIGF-1 injections simultaneously with a meal, monitoring glucose levels and paying special attention to the risk of hypoglycemia after exercise. For this study, no attempts were made to document the potential relationship between hypoglycemia and the development of headache.

A potential limitation of this study was that pretreatment HVs were not available because a specific pretreatment HV cutoff was not part of the inclusion criteria. As study participants had to be ≥5 years of age and prepubertal, one can assume that the average pretreatment growth velocity was around 5.0–6.5 cm per year. Furthermore, the administration of two injections per day with coadministration therapy (vs. only one with monotherapy) could lead to decreased long-term compliance and treatment adherence, although there was no evidence of this in this study. An additional limitation is the absence of an rhIGF-1 alone treatment arm. Finally, a significant number of patients entered puberty during the study, possibly affecting treatment response, but when analysis of the HV ANCOVA was done for the pubertal status, it did not affect the observed statistical significance of the primary analysis.

It remains too early to state that combination therapy will ultimately improve adult height beyond rhGH monotherapy intervention. However, recent reports have underscored that clinical expression of GH–IGF-I axis defects runs along a continuum of genetic, phenotypic and hormonal abnormalities [1, 31–33]. The associated IGFD may then reflect the existence of a spectrum of GH sensitivity that is much wider than initially believed based on the extremes of severe GH deficiency or GH insensitivity [34]. The therapeutic applicability of GH–IGF-1 combination therapy may therefore apply to specific subpopulations within the GH–IGF-1 axis continuum, such as GH-deficient patients with suboptimal response to rhGH therapy and patients with milder forms of GH insensitivity.

**Conclusion**

In GH-sufficient children with short stature and low IGF-I, coadministration of 45 rhGH + 150 rhIGF-1 (both μg/kg/day) significantly accelerated statural growth compared with rhGH monotherapy. A significant difference in HV between the 45 rhGH + 150 rhIGF-1 and rhGH alone groups was observed at year 1. This resulted in a sustained height SD score improvement, as this effect persisted during the second and the third years of treatment. Treatment with rhGH/rhIGF-1 coadministration was generally well tolerated, with a safety profile similar to the individual monotherapies. Despite these results, we cannot recommend that rhGH/rhIGF-1 combination therapy be considered for GH-sufficient short children with low IGF-1. However, because in select patients this treatment approach may lead to improved growth compared with either rhGH or rhIGF-1 monotherapy, our findings indicate a need for further studies.

**Acknowledgements**

This study was sponsored and funded by Ipsen, France. The authors take full responsibility for the content of this manuscript and would like to thank Communigen Ltd. (Oxford, UK), funded by Ipsen, France, for assisting with the preparation of this manuscript. The authors wish to thank the study coordinators and the other MS316 investigators (listed below), and the following individuals who were involved in the study design and conduct: George Bright, Catherine Lesage, Pascal Birman and Sandra Blethen, as well as Stephen Chang who also contributed to the data analyses. The MS316 Study Group includes, in California, Susan Clark, Rudveep Randhawa, Michael Gottschalk, Norman Lavin, Gnanagurudasan Prakasam; in Florida, Larry Deeb; in Georgia, Quentin Van Meter; in Illinois, Richard Levy; in Indiana, John Fuqua; in Massachusetts, Rosalind Brown, Leslie Soyka; in Minnesota, Betsy Schwartz; in Missouri, Maxwell Feldt; in New Jersey, Dennis Brenner, Lawrence Silverman; in Ohio, Douglas Rogers; in Oregon, Katie Woods; in Pennsylvania, Stephen Willi; in South Carolina, Deborah Bowlby; in Texas, Michele Hutchison, Louisa Rodriguez, and in Washington, Patricia Fechner. We would also like to thank the members of the Data Monitoring Committee: Alan Rogol, Mitchell Geffner, Laurie Cohen and Charles DuMond.

**Disclosure Statement**

P.F.B. was an investigator on the trial, has been an advisory committee member for Ipsen, has received research funding from Ipsen and Novo Nordisk, and has received consultancy fees from Novo Nordisk, Sandoz and EMD Serono; B.S.M. was an investigator on the trial, has received consultancy fees from Alexion, BioMarin, Ipsen, Genentech, Novo Nordisk, Sandoz and Endo Pharmaceuticals, and has received research funding from Ipsen, Genentech, Pfizer, Novo Nordisk, Eli Lilly & Company, Sandoz, Endo Pharmaceuticals and AbbVie; P.D. is an employee of Ipsen Innovation; A.H. is an employee of Ipsen Pharma; E.L. is a former employee of Ipsen Biopharmaceuticals; D.E.H. was an investigator on this trial; B.R. was an investigator on the trial, and has received consultancy fees from Ipsen and research funding from Ipsen, Genentech, Pfizer and Novo Nordisk, and M.A.S. has received consultancy fees from Novo Nordisk.

Backeljauw et al.
References


